Six weeks after weathering a severe stock market storm, Paul Hudson, Sanofi's chief executive, is back on deck this Thursday in New York to convince investors. On 27 October, this French flagship of the CAC40 plunged by 19% on the stock market, sending a €25 billion market capitalization soaring. The violent sanction of the group's abandonment of its objective of reaching a margin of 32% by 2025, justified by an increase in investments in R&D.
The announcement of the spin-off of its consumer health division, which includes its over-the-counter drugs including the famous Doliprane, was not enough to calm investors' headaches. Worse, the "new chapter" of the strategy that the British leader promised to write has remained inaudible. Since then, the stock has barely recovered, proof of the markets' mistrust of Sanofi.
"We need to attract new investors"
"The investors I've met with since October 27 have given us an A for the strategy presented that day, but a C+ for...
This article is for subscribers only. You still have 89% to discover.
Want to read more?
Unlock all items immediately.
TEST FOR €0.99
Already a subscriber? Log